An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

NCT01796301 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

436

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Romozosumab
DRUG: Teriparatide

Sponsor

Amgen